In Jan. 2005, the U.S. Food and Drug Administration approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane) for use in the treatment of metastatic or recurrent breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.